Brand Name
Enjaymo
Generic Name
Sutimlimab-Jome
View Brand Information FDA approval date: February 04, 2022
Classification: Classical Complement Pathway Inhibitor
Form: Injection
What is Enjaymo (Sutimlimab-Jome)?
ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease . Cold Agglutinin Disease ENJAYMO is indicated for the treatment of hemolysis in adults with cold agglutinin disease .
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment